Evidence map›Paper›PMID 39868801›Full record

ArticleJournal of virology2025

APOBEC-1 cofactors regulate APOBEC3-induced mutations in hepatitis B virus.

Zhigang Chen, Thomas L Eggerman, Alexander V Bocharov, Irina N Baranova, Tatyana G Vishnyakova, Amy P Patterson

Abstract read
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Occult hepatitis B virus infection.Nature reviews. Gastroenterology & hepatology · 2026
    Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhigang ChenDepartment of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Thomas L EggermanDepartment of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Alexander V BocharovDepartment of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Irina N BaranovaDepartment of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Tatyana G VishnyakovaDepartment of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Amy P PattersonDepartment of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0009-0005-2356-0814

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

APOBEC3 proteins (A3s) play an important role in host innate immunity against viruses and DNA mutations in cancer. A3s-induced mutations in both viral and human DNA genomes vary significantly from non-lethal mutations in viruses to localized hypermutations, such as kataegis in cancer. How A3s are regulated remains largely unknown. Since A3s exist in complexes and belong to the same family as APOBEC-1 (A1), which requires cofactors to be functional, we investigated the role of A1 cofactors and other A3 potentially associated hnRNPs on A3 mutational activity using hepatitis B virus (HBV) cellular replication as a model. We found that A1-associated cofactors and other hnRNPs were involved in A3 mutational activity regulation, and their regulatory effect was dependent on the strength of A3 association with hnRNPs with an order of A3C > 3G>3B and A1 cofactors > other hnRNPs. A1 cofactors had a strong protein interaction with A3 and significantly increased A3 mutational activity by co-expression. Endogenous gene expression knockdown by siRNA had the opposite decrease effect. Disruption of the protein interactions between A3 and hnRNPs through A3G and A3B mutagenesis decreased A3 mutational activity significantly, even to a level of near total loss, indicating that A1 cofactors and hnRNPs are required for A3 mutational activity. HBV genome-wide mutation analyses showed that A1 cofactors significantly increased A3C accessibility to HBV (-)DNA and A3C-induced mutational efficiency to generate kataegis-like hypermutation. These data demonstrate that A1 cofactors and hnRNPs are closely associated with A3s and may play an important regulatory role under physiological conditions. IMPORTANCE: As human host restriction factors, A3s play an important role against viral infections. A3s are also major mutagenic drivers of cancer. However, why A3-induced mutations vary significantly from non-lethal mutations in virus to localized hypermutations in cancer remains unknown. We found that A1 cofactor and other hnRNPs are not only associated with A3 complexes but also play important regulatory roles in A3-induced mutation activities. A1 cofactors like GRY-RBP significantly increased A3 accessibility and mutational efficiency to its single-strand DNA substrate during HBV reverse transcription to generate hypermutations. Disruption of the A3 protein association with hnRNPs by A3 mutagenesis diminished A3 mutational activity. This finding not only reveals a regulatory mechanism for A3-induced mutation but also indicates that A3-associated cellular factors can be a potential target for regulating A3-induced mutation for cancer therapeutics.

Indexed as

APOBEC-1 DeaminaseCytidine DeaminaseHepatitis B virusMutationAPOBEC DeaminasesDNA, ViralHepatitis BHumansVirus ReplicationAPOBEC-1 DeaminaseAPOBEC1 protein, humanAPOBEC3 proteins, humanAPOBEC DeaminasesCytidine DeaminaseDNA, ViralAPOBEC3cofactorhepatitis B virushnRNPhypermutationmutationregulation

Identifiers

PMID39868801
PMCPMC11853063

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.